GLP-1 agonist for diabetes after spinal cord injury
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Injuries & trauma clinical trials.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have a spinal cord injury that happened more than one year ago.
- You have type 2 diabetes and your blood sugar is managed with diet and metformin only.
- Your HbA1c is between 6.0 and 9.0%.
- Your BMI is over 22 kg/m2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new type of diabetes medicine, called a GLP-1 receptor agonist, affects heart artery health in people with type 2 diabetes who recently had a heart procedure. It aims to find out if adding this medicine can further protect the heart and improve recovery.
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
Hear when a new Spinal Cord Injuries trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.